| Autor: |
Shaforostova EA; Voronezh State University, Voronezh, Russia., Gureev AP; Voronezh State University, Voronezh, Russia; Voronezh State University of Engineering Technologies, Voronezh, Russia., Vitkalova IY; Voronezh State University, Voronezh, Russia; Voronezh State University of Engineering Technologies, Voronezh, Russia., Popov VN; Voronezh State University, Voronezh, Russia; Voronezh State University of Engineering Technologies, Voronezh, Russia. |
| Abstrakt: |
Meldonium is a metabolic drug used for treatment of coronary heart disease. The effect of the drug lies in its ability to inhibit synthesis and transport of L-carnitine. At the same time, a long-term deficiency of L-carnitine can theoretically negatively affect the activity of the transcription factor Nrf2, which is extremely important for maintaining mitochondrial balance in cells. We have shown that meldonium therapy for 3 months at a dose of 100 mg/kg in mice causes a decrease in the expression of the Nrf2 gene in the brain. A decrease in the Nrf2 level causes suppression of mitochondrial biogenesis, which is manifested in a decrease in the level of mtDNA and the level of Cox1 expression. However, no negative effect of meldonium on the bioenergetics parameters of mitochondria was found, as evidenced by the maintenance of a stable mitochondrial potential and the level of production of reactive oxygen species. Jne mohth after the end of the meldonium therapy, expression of the genes responsible for mitochondrial biogenesis and mitophagy (p62, Pink1, Tfam) was observed and the expression level of genes responsible for mitochondrial fusion returned to control values. These changes may be associated with the normalization of the level of L-carnitine in brain cells. |
